biote Corp. (NASDAQ:BTMD) Short Interest Up 22.6% in January

biote Corp. (NASDAQ:BTMD) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,477,700 shares, an increase of 22.6% from the December 31st total of 1,205,571 shares. Based on an average daily volume of 206,954 shares, the short-interest ratio is presently 7.1 days. Currently, 4.3% of the company’s shares are short sold. Currently, 4.3% of the company’s shares are short sold. Based on an average daily volume of 206,954 shares, the short-interest ratio is presently 7.1 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wall Street Zen cut biote from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. B. Riley restated a “neutral” rating on shares of biote in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of biote in a report on Monday, December 29th. Finally, Truist Financial set a $5.00 price target on shares of biote in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, biote presently has a consensus rating of “Hold” and a consensus price target of $5.67.

biote Stock Up 3.7%

NASDAQ BTMD opened at $2.22 on Thursday. The firm has a market capitalization of $101.37 million, a PE ratio of 2.81 and a beta of 1.15. The stock’s 50 day moving average is $2.50 and its 200 day moving average is $2.92. biote has a twelve month low of $2.03 and a twelve month high of $5.15.

biote (NASDAQ:BTMD) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.17. biote had a net margin of 14.72% and a negative return on equity of 21.86%. The company had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $47.76 million. On average, research analysts anticipate that biote will post 0.75 earnings per share for the current year.

Institutional Investors Weigh In On biote

Several institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio increased its holdings in biote by 50.9% in the 4th quarter. Strs Ohio now owns 166,300 shares of the company’s stock worth $432,000 after buying an additional 56,100 shares in the last quarter. Man Group plc boosted its holdings in shares of biote by 9.9% during the 3rd quarter. Man Group plc now owns 70,383 shares of the company’s stock valued at $211,000 after acquiring an additional 6,356 shares during the last quarter. Occudo Quantitative Strategies LP bought a new stake in shares of biote in the third quarter worth approximately $61,000. Squarepoint Ops LLC purchased a new position in shares of biote during the third quarter valued at approximately $49,000. Finally, Franklin Resources Inc. bought a new position in biote during the third quarter valued at approximately $58,000. Institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.